A clear vision for the future

25 September 2025
Acuity digital

What the NHS 10-Year Health Plan means for optometry in England

Published 3 July 2025, the NHS 10-Year Health Plan outlines the Westminster Government’s bold vision for healthcare in England. For optometry, it presents an unprecedented opportunity – one we must not miss.

Encouragingly, many proposals echo long-standing priorities championed by The College of Optometrists. Optometry has long been ready to step up to the frontline of NHS care. Now, we must ensure the profession is central to delivering this vision.

A national shift: care closer to home

At the heart of the Plan is a shift towards delivering more care outside hospitals. New Neighbourhood Health Centres will host multidisciplinary teams from across health, social care, and the voluntary sector.

This community-first model offers huge potential for eye care. Optical practices are already embedded in communities – accessible, well-equipped, and professionally staffed – making them ideal as first “neighbourhood” contact for eye health concerns. They should work alongside the new Neighbourhood Health Centres; there’s no need to reinvent or relocate them to be part of them. Enhanced services, including urgent and minor eye conditions, cataract post-op checks and glaucoma monitoring, are ready to scale. These reduce pressure on GPs and hospital departments and ensure faster, more convenient care. 

Sign in to continue

Forgotten password?
Register

Not already a member of the College?

Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.

Related further reading

In our response, we have highlighted the critical role of primary eye care and the optometric workforce in delivering integrated, cost-effective NHS services.

The new framework recognises primary eye care as fundamental to NHS provision and local leadership.

The Medicine & Healthcare products Regulatory Agency (MHRA) has approved the first licensed low-dose atropine (LDA) treatment for slowing the progression of childhood myopia.